Systimmune Inc. and Bristol Myers Squibb Co. have joined hands in a co-development deal for bispecific antibody drug conjugate (ADC) BL-B01D1 in a deal worth up to $8.4 billion. The deal falls on the heels of BMS acquiring Mirati Therapeutics in October 2023 for $4.8 billion to add to its oncology pipeline.
Systimmune Inc. and Bristol Myers Squibb Co. have joined hands in a co-development deal for bispecific antibody drug conjugate (ADC) BL-B01D1 in a deal worth up to $8.4 billion. The deal falls on the heels of BMS acquiring Mirati Therapeutics in October 2023 for $4.8 billion to add to its oncology pipeline.
Tarapeutics Science Inc. has divulged tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, fibrosis, immunological, eye and cardiovascular disorders.
Researchers at Admare Bioinnovations, Lifearc and Provincial Health Services Authority (PHSA) have disclosed DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
DNA topoisomerase I (TOP1) is an enzyme that has a direct role in transcriptional regulation, and thus has an impact on cell growth and may be considered a therapeutic target for cancer treatment. Previous research showed that high concentration release of nitric oxide (NO) together with TOP1 inhibition may be an effective strategy in promoting tumor cell apoptosis.
High expression of CD123, the IL-3 receptor α chain (IL-3α), is observed on both leukemic blasts and leukemic stem cells, thus suggesting it can be considered an attractive therapeutic target in AML.
Pasithea Therapeutics Corp. has reported promising preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 (CIP-137401), a small-molecule allosteric inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2), in NRAS mutation cancer xenograft models.
Katy Rezvani received this year’s E. Donnall Thomas Prize for her work on natural killer (NK) cells at the annual meeting of the American Society of Hematology (ASH). It was not love at first sight, though.
Biomea Fusion Inc.’s diabetes treatment produced enhanced glycemic control at week 26 courtesy of its 200-mg cohort. It’s the latest advance for the company’s candidate that also has strong prospects in treating leukemia. Top-line data from the ongoing phase II Covalent-111 study of BMF-219, a covalent menin inhibitor for regenerating insulin-producing beta cells, demonstrated that about 40% of participants, four of 11 patients, in the 200-mg cohorts showed a durable reduction, 1% or more, in the amount of blood sugar attached to the type 2 diabetes (T2D) patients’ hemoglobin. The data came from participants who had received the last dose in a four-week treatment.
Prescient Therapeutics Pty Ltd.’s PTX-100 met primary safety endpoints and showed preliminary efficacy in a phase Ib trial in patients with relapsed and refractory T-cell lymphomas that exceeded the standard of care, and the company hopes to advance to a phase II registrational study in 2024, Prescient CEO Steven Yatomi-Clarke told BioWorld.
RSS
